| Methods |
RCT.
Partially masked.
Active controlled. |
| Participants |
68 people with POAG, proportion of PEX and PDS unknown.
7% African American.
inclusion criteria: IOP equal or above 24 mmHg, disc and visual field abnormality, PEX and PG allowed.
Exclusion criteria: history of ocular trauma, uveitis, inflammatory disease and recent ocular infection, intraocular surgery within 6 months and laser trabeculoplasty within 3 months, systemic glucocorticoids and medication that may affect IOP. |
| Interventions |
Timolol 0.5% BID.
Betaxolol 0.5% BID.
Pilocarpine 2% 4 times daily. |
| Outcomes |
Change in visual field mean defect.
IOP. |
| Notes |
2 years follow up.
Timolol and betaxolol masked, pilocarpine open label. No difference between groups.
Drop‐outs due to drug‐related adverse events: 5 timolol, 1 betaxolol, 3 pilocarpine (unspecified whether local or systemic side effects). |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
